Find Out If You Have a Case

Free, confidential review by Attorney Matthew T. Marin. Prefer to talk? Call (888) 348-2735.

Super Lawyers® 2014–2024CALL 24/7(888) 348-2735

Dupixent Lawsuit — Free, Confidential Case Review

Do you qualify for the Dupixent lawsuit?

Most people aren’t sure. The answer turns on your diagnosis and timing — two confidential minutes, no documents needed.

ACTIVE LITIGATION — NO SETTLEMENT. MDL 3180 underway · filing deadlines vary by state.

Were you — or someone you love — diagnosed with CTCL or another T-cell lymphoma after taking Dupixent?

Check if my case qualifiesfree · confidential · takes 2 minutes
I’m not sure of my exact diagnosis →

No documents needed · confidential · an answer either way · no fee unless there is a recovery. Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney’s fee is a percentage of the gross recovery, calculated before expenses are deducted.

Or talk to a person now: (888) 348-2735 — answered 24/7

Stefanie A. Murphy & Matthew T. Marin

Partners

Every Dupixent inquiry gets a personal review — and an honest answer either way, free and without obligation.

Claims are brought against Sanofi and Regeneron, the makers of Dupixent — not against your doctor. Conversations are confidential. Some matters may be referred to other lawyers. No settlement has been reached, and most cases are in their earliest stages; every case must be proven on its own facts. Attorney Advertising.

This page is about a lawsuit — it is not medical advice, and filing a claim does not require you to stop taking Dupixent. Decisions about your medication belong with you and your doctor.

Lawsuits consolidated in MDL 3180 (D.N.J.) allege that Dupixent (dupilumab) is associated with an increased risk of cutaneous T-cell lymphoma (CTCL) and that the manufacturers failed to warn about it. No court has ruled on these allegations, no settlement exists, and the litigation is in its earliest stages. Published studies report a statistical association — which the study authors themselves note does not establish causation — and the FDA has identified a potential safety signal it is still evaluating; Dupixent’s FDA label does not currently warn about lymphoma. Whether any individual has a claim depends on their medical records and the law of their state.

Who Qualifies for the Dupixent Lawsuit?

The Dupixent lawsuit is a set of individual claims consolidated in federal court as MDL 3180 in the District of New Jersey, and qualification comes down to two questions:

• Did you take Dupixent? Any use counts — there is no requirement about how long you were on it.
• Were you diagnosed with CTCL or a qualifying T-cell lymphoma subtype during or after that use? “During” matters: a diagnosis made while you were still on the drug qualifies the same as one made after you stopped.

That is the whole test. Everything else — dates, records, subtype details, your state’s timing rules — is worked out in a free review from your records, not something you need to figure out before reaching out. Marin & Murphy Law Firm is currently accepting Dupixent CTCL cases.

Which Lymphoma Diagnoses Qualify?

The qualifying diagnoses are broader than the strict label “CTCL” — a point many pages get wrong. Fourteen T-cell lymphoma subtypes meet the diagnosis criterion, including the most common form, mycosis fungoides, and Sézary syndrome:

• T-Cell Lymphoma
• Cutaneous Lymphoma
• Anaplastic Large Cell Lymphoma
• Null Cell Types
• Mycosis Fungoides
• Sézary Syndrome
• Cutaneous Gamma/Delta T-Cell Lymphoma
• Epidermotropic Cytotoxic T-Cell Lymphoma
• Peripheral T-Cell Lymphoma
• Angioimmunoblastic T-Cell Lymphoma
• Adult T-Cell Lymphoma/Leukemia
• Composite Lymphoma
• Lymphomatoid Papulosis
• Natural Killer (NK)–Cell Lymphoblastic Lymphoma

If your diagnosis was described to you only as “T-cell lymphoma,” “skin lymphoma,” or even “a type of blood cancer that affects the skin,” and you are not sure which subtype it is — that does not end the inquiry. The precise subtype lives in your pathology report, and finding it there is part of the review.

Do You Need a Minimum Time on Dupixent?

No. Some sites claim you need a month of use — that is not the criteria we apply. There is no minimum duration of use in the qualifying criteria: a single injection followed by a qualifying diagnosis is reviewable. The reason is straightforward — the legal questions in this litigation turn on what the manufacturers allegedly knew and failed to warn about, and on what your medical records show about your diagnosis and its timing. An arbitrary one-month floor answers none of those questions, which is why we do not use one.

What If Your Loved One Has Died?

Claims may be brought on behalf of a person who has died, through their estate — the wrongful death route. Typically that means an appointed personal representative brings the claim under state wrongful-death and survival laws; if no estate has been opened yet, that is a solvable step, not a barrier. The diagnosis criteria are the same, and records — a pathology report, pharmacy history, treatment records — do the work that memory does not have to. Take whatever time you need; the evaluation is free, and there is no script to follow in that conversation.

What Disqualifies a Dupixent Claim?

One thing, absolutely: if another attorney or law firm already represents you for this claim, we cannot review it. That is the single hard disqualifier. Beyond that, the criteria themselves do the sorting — someone who never took Dupixent has no claim to review, and this litigation concerns T-cell lymphoma diagnoses, not other conditions.

What about symptoms without a diagnosis? If you have a rash or patch you are worried about but no lymphoma diagnosis, this page cannot tell you what it is — and it should not try. Only a doctor and, where appropriate, a biopsy can answer that question, and we would encourage you to raise your concern with your physician rather than with a law firm. If a qualifying diagnosis ever comes, the criteria on this page will still be here.

What About Filing Deadlines?

Deadlines vary by state. Every state sets its own statute of limitations, the clocks start from different events in different states, and some states allow as little as one year; the state pages set out the rule that applies in each state. We state this because it is true, not to rush you: it is a fact about state law, and checking the timing rules for your state is part of the free evaluation, not your job to research first.

Prefer to check online? The free confidential qualification quiz takes about two minutes and applies the exact criteria on this page — including the “not sure of my subtype” path, which never dead-ends.

What Happens After You Reach Out?

A short, confidential conversation about your Dupixent use, your diagnosis, and your treatment — followed, if the criteria fit, by a records review. Whether a claim is accepted is determined after that review, and no attorney-client relationship is created until a written engagement agreement is signed. You will get a straight answer either way, and if the answer is no, you will know why.

Dupixent Qualification FAQs